Business
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
Partner Sanofi plans to initiate Phase 2 trial of IRAK4 degrader KT-474 (SAR444656) in 2023 Phase 1 trials for STAT3 (KT-333) and IRAKIMiD (KT-413) degraders
About this update from Kymera Therapeutics, Inc.
[{"type":"text","content":"Partner Sanofi plans to initiate Phase 2 trial of IRAK4 degrader KT-474 (SAR444656) in 2023 Phase 1 trials for STAT3 (KT-333) and IRAKIMiD (KT-413) degraders ongoing,with data evaluating clinical activity expected to be shared in 2023 Phase 1 clinical trial for MDM2 degrader (KT-253) expected to be initiated in early 2023 Year-end 2022 cash balance of approximately $560 million with cash runway into second half of 2025 Company to hold quarterly results call at 8:30 a.m. ET WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022. “2022 was a significant year for Kymera, with our clinical data validating critical aspects of our approach to drug discovery and development, moving us forward toward becoming a fully integrated global biopharmaceutical company. Our lead program, KT-474, demonstrated the first clinical impact of a degrader outside of oncology in complex inflammatory diseases, and also showed the superior clinical potential of an IRAK4 degrader compared to a small molecule inhibitor, confirming our platform and target selection strategy. In addition, we are excited that programs from our oncology pipeline continue to show fidelity of translation of PK, PD and tolerability from preclinical models to human patients, validating our proprietary molecular design and translational capabilities,” said Nello Mainolfi, PhD, Co-Founder, President and CEO. “Looking ahead, we plan to share important data from our oncology programs this year, including clinical data evaluating anti-tumor activity with our STAT3 (KT-333) and IRAKIMiD (KT-413) programs. With four clinical stage programs, a proprietary discovery engine designed to enable us to add one new program to our clinical pipeline each year, and a strong financial position that will enable us to continue to invest in our platform and pipeline, we are well-positioned to deliver on our goals and improve patients’ lives with a new generation of medicines.” Recent Business Highlights and Developments In December, Kymera announced positive results from the Phase 1 clinical trial evaluat...